Laparoscopic splenic hilum lymph node dissection for advanced proximal gastric cancer: A modified approach for pancreas- and spleen-preserving total gastrectomy

Table 1 Clinicopathological characteristics of patients

Patient No.	Gender	Age (yr)	BMI (kg/mkg/m2)	Tumor location	Tumor size (cm)	Tumor depth1	TNM stage1	No. of retrieved LN2	No. of metastatic LN2	No. of retrieved splenic hilum LN2	No. of metastatic splenic hilum LNc
1	Male	60	19.1	U	5.0	T4a	IIIC	21	7	3	0
2	Male	73	24.8	U	6.0	T4a	IIIB	18	5	4	0
3	Male	61	20.6	U	8.5	T4a	IIIA	34	2	8	0
4	Male	62	20.2	U	7.0	T3	IIA	39	0	4	0
5	Male	59	20.8	U	4.5	T4a	IIB	16	0	3	0
6	Female	54	20.4	M	5.0	T4a	IIIA	20	1	5	0
7	Female	57	24.0	U	5.0	T4a	IIIA	20	1	7	0
8	Male	57	19.1	U	8.0	T4a	IIIC	28	21	6	3
9	Male	61	25.6	U	3.5	T4a	IIIA	16	2	4	0
10	Male	63	21.1	M	2.9	T4a	IIB	24	0	5	0
11	Female	75	21.8	U	5.5	T4a	IIIB	19	3	2	0
12	Male	45	20.6	M	4.0	T4a	IIB	35	0	6	0

¹“Tumor depth” and “Tumor node metastasis (TNM) stage” were in accordance with the AJCC cancer staging manual-7^th edition;

²Lymph nodes (LN). BMI: Body mass index.

Table 2 Surgical outcomes, postoperative course and follow-up data of patients

Patient No.	Operating time (min)	Estimated blood loss (mL)	Time to first flatus (POD)	Time to soft diet (POD)	Hospital stay (POD)	Follow-up (mo)	Follow-up outcome
1	230	50	5	10	10	37	No recurrence, alive
2	352	300	6	10	13	37	No recurrence, alive
3	180	100	4	8	11	36	No recurrence, alive
4	314	100	5	7	10	28	No recurrence, alive
5	278	100	4	8	12	24	No recurrence, alive
6	305	100	2	9	11	24	No recurrence, alive
7	298	300	5	8	12	24	No recurrence, alive
8	260	150	2	4	8	18	Peritoneal metastasis, death
9	280	200	3	5	6	6	No recurrence, alive
10	223	50	2	6	7	5	No recurrence, alive
11	221	150	3	4	5	4	No recurrence, alive
12	280	200	3	7	8	1	No recurrence, alive

POD: Postoperative days.

Table 3 Surgical outcomes and postoperative courses of laparoscopic pancreas- and spleen-preserving splenic hilum lymph nodes dissection

Items	mean ± SD (range)
Operating time (min)	268.4 ± 48.0 (180-352)
Estimated blood loss (mL)	150.0 ± 85.3 (50-300)
No. of retrieved LN	24.2 ± 7.9 (16-39)
No. of metastatic LN	3.5 ± 5.9 (0-21)
No. of retrieved splenic hilum LN	4.8 ± 1.8 (2-8)
No. of metastatic splenic hilum LN	0.3 ± 0.9 (0-3)
Time to first flatus (POD)	3.7 ± 1.4 (2-6)
Time to soft diet (POD)	7.2 ± 2.1 (4-10)
Hospital stay (POD)	9.4 ± 2.6 (5-13)
Intraoperative complication	1 (8.3%)
Postoperative complication	0
Mortality	0

LN: Lymph nodes; POD: Postoperative days.